Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameLiothyronine
Accession NumberDB00279  (APRD01074)
Typesmall molecule
Groupsapproved
Description

The L-triiodothyronine (T3, liothyronine) thyroid hormone is normally synthesized and secreted by the thyroid gland in much smaller quantities than L-tetraiodothyronine (T4, levothyroxine, L-thyroxine). Most T3 is derived from peripheral monodeiodination of T4 at the 5 position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
3,3',5-triiodo-L-thyronineNot AvailableNot Available
3,5,3'-Triiodo-L-thyronineNot AvailableNot Available
3,5,3'-TriiodothyronineNot AvailableNot Available
L-3,5,3'-TriiodothyronineNot AvailableNot Available
L-T3Not AvailableNot Available
O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosineNot AvailableNot Available
T3Not AvailableNot Available
TriiodothyronineNot AvailableNot Available
Salts
Name/CAS Structure Properties
Liothyronine Sodium
55-06-1
Thumb
  • InChI Key: SBXXSUDPJJJJLC-YDALLXLXSA-M
  • Monoisotopic Mass: 672.77198278
  • Average Mass: 672.9553
DBSALT000321
Brand names
NameCompany
CytomelNot Available
TertroxinNot Available
TresitopeNot Available
TriostatNot Available
Brand mixtures
Brand NameIngredients
LiotrixLevothyroxine + Liothyronine
ThyrolarLevothyroxine + Liothyronine
CategoriesNot Available
CAS number6893-02-3
WeightAverage: 650.9735
Monoisotopic: 650.790038137
Chemical FormulaC15H12I3NO4
InChI KeyInChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
IUPAC Name
(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
SMILES
N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassPhenylpropanoids and Polyketides
ClassPhenylpropanoic Acids
SubclassNot Available
Direct parentPhenylpropanoic Acids
Alternative parentsDiarylethers; Amphetamines and Derivatives; Alpha Amino Acids and Derivatives; o-Iodophenols; Phenol Ethers; Amino Fatty Acids; Iodobenzenes; Aryl Iodides; Polyols; Enolates; Carboxylic Acids; Enols; Polyamines; Monoalkylamines; Organoiodides
Substituents2-iodophenol; 2-halophenol; phenol ether; iodobenzene; phenol derivative; benzene; aryl iodide; aryl halide; polyol; enolate; polyamine; carboxylic acid derivative; carboxylic acid; enol; ether; amine; organohalogen; organoiodide; primary aliphatic amine; organonitrogen compound; primary amine
Classification descriptionThis compound belongs to the phenylpropanoic acids. These are compounds whose structure contain a benzene ring conjugated to a propanoic acid.
Pharmacology
IndicationUsed as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyrodism during the recovery phase of subacute thyroiditis.
PharmacodynamicsThyroid hormone drugs are natural or synthetic preparations containing T4 or T3 or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. Liothyronine (T3) contains three atoms of iodine and is formed by the coupling of one molecule of diiodotyrosine (DIT) with one molecule of monoiodotyrosine (MIT). These hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system.
Mechanism of actionThe hormones, T4 and T3, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major form of thyroid hormone in the blood is thyroxine (T4). This is converted to the more active liothyronine form by deiodinases in peripheral tissues. Liothyronine acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). The thyroid hormones are essential to proper development and differentiation of all cells of the human body. To various extents T4 and T3 regulate protein, fat and carbohydrate metabolism. Their most pronounced effect is on how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.
Absorption95% in 4 hours
Volume of distributionNot Available
Protein binding99.7%
Metabolism
SubstrateEnzymesProduct
Liothyronine
    Triiodothyronine sulfateDetails
    Route of eliminationNot Available
    Half life2.5 days
    ClearanceNot Available
    ToxicityNot Available
    Affected organisms
    • Humans and other mammals
    PathwaysNot Available
    SNP Mediated EffectsNot Available
    SNP Mediated Adverse Drug ReactionsNot Available
    ADMET
    Predicted ADMET features
    Property Value Probability
    Human Intestinal Absorption + 0.7212
    Blood Brain Barrier - 0.6886
    Caco-2 permeable - 0.653
    P-glycoprotein substrate Non-substrate 0.5321
    P-glycoprotein inhibitor I Non-inhibitor 0.9175
    P-glycoprotein inhibitor II Non-inhibitor 0.9709
    Renal organic cation transporter Non-inhibitor 0.8891
    CYP450 2C9 substrate Non-substrate 0.8309
    CYP450 2D6 substrate Non-substrate 0.9116
    CYP450 3A4 substrate Non-substrate 0.6847
    CYP450 1A2 substrate Non-inhibitor 0.5924
    CYP450 2C9 substrate Non-inhibitor 0.7037
    CYP450 2D6 substrate Non-inhibitor 0.923
    CYP450 2C19 substrate Non-inhibitor 0.9025
    CYP450 3A4 substrate Non-inhibitor 0.831
    CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8459
    Ames test Non AMES toxic 0.7591
    Carcinogenicity Non-carcinogens 0.9148
    Biodegradation Not ready biodegradable 0.9693
    Rat acute toxicity 2.7082 LD50, mol/kg Not applicable
    hERG inhibition (predictor I) Weak inhibitor 0.9697
    hERG inhibition (predictor II) Non-inhibitor 0.8508
    Pharmacoeconomics
    Manufacturers
    • X gen pharmaceuticals inc
    • Jhp pharmaceuticals llc
    • King pharmaceuticals inc
    • Coastal pharmaceuticals inc
    • Mylan pharmaceuticals inc
    • Watson laboratories inc
    Packagers
    Dosage forms
    FormRouteStrength
    InjectionIntravenous10 mcg/ml
    TabletOral25 mcg
    TabletOral5 mcg
    TabletOral50 mcg
    Prices
    Unit descriptionCostUnit
    Triostat 10 mcg/ml vial627.9USDml
    Cytomel 50 mcg tablet1.89USDtablet
    Liothyronine Sodium 50 mcg tablet1.69USDtablet
    Liothyronine sod 50 mcg tablet1.62USDtablet
    Cytomel 25 mcg tablet1.21USDtablet
    Cytomel 25 mcg Tablet1.2USDtablet
    Cytomel 5 mcg Tablet1.11USDtablet
    Liothyronine Sodium 25 mcg tablet1.09USDtablet
    Liothyronine sod 25 mcg tablet1.06USDtablet
    Cytomel 5 mcg tablet0.89USDtablet
    Liothyronine Sodium 5 mcg tablet0.84USDtablet
    Liothyronine sod 5 mcg tablet0.81USDtablet
    DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
    PatentsNot Available
    Properties
    Statesolid
    Experimental Properties
    PropertyValueSource
    melting point236.5 dec °CPhysProp
    water solubility3.96 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
    logP2.9Not Available
    logS-5.22ADME Research, USCD
    Predicted Properties
    PropertyValueSource
    water solubility1.95e-02 g/lALOGPS
    logP0.82ALOGPS
    logP2.8ChemAxon
    logS-4.5ALOGPS
    pKa (strongest acidic)0.3ChemAxon
    pKa (strongest basic)9.48ChemAxon
    physiological charge0ChemAxon
    hydrogen acceptor count4ChemAxon
    hydrogen donor count3ChemAxon
    polar surface area92.78ChemAxon
    rotatable bond count5ChemAxon
    refractivity113.43ChemAxon
    polarizability43.92ChemAxon
    number of rings2ChemAxon
    bioavailability1ChemAxon
    rule of fiveNoChemAxon
    Ghose filterNoChemAxon
    Veber's ruleNoChemAxon
    MDDR-like ruleNoChemAxon
    Spectra
    Spectra
    References
    Synthesis Reference

    Martin Beasley, David Hause, Irwin Klein, Charles Pamplin, David Reynolds, Kevin Sills, “Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same.” U.S. Patent US20060246133, issued November 02, 2006.

    US20060246133
    General Reference
    1. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H: Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002 Apr;61(4):729-37. Pubmed
    External Links
    ResourceLink
    KEGG CompoundC02465
    PubChem Compound5920
    PubChem Substance46506352
    ChemSpider5707
    BindingDB18860
    ChEBI18258
    ChEMBLCHEMBL1544
    Therapeutic Targets DatabaseDAP000082
    PharmGKBPA164778866
    IUPHAR2634
    Guide to Pharmacology2634
    HETT3
    Drug Product Database1919466
    RxListhttp://www.rxlist.com/cgi/generic3/liothyronine.htm
    Drugs.comhttp://www.drugs.com/cdi/liothyronine.html
    WikipediaLiothyronine
    ATC CodesH03AA02
    AHFS Codes
    • 68:36.04
    PDB EntriesNot Available
    FDA labelshow(40.8 KB)
    MSDSshow(73.4 KB)
    Interactions
    Drug Interactions
    Drug
    Calcium AcetateCalcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
    Calcium ChlorideCalcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.
    CholestyramineThe resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine.
    ColestipolThe resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine.
    DigoxinThe thyroid hormone, liothyronine, decreases the effect of digoxin.
    WarfarinLiothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed.
    Food InteractionsNot Available

    1. Thyroid hormone receptor alpha

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Actions: agonist

    Components

    Name UniProt ID Details
    Thyroid hormone receptor alpha P10827 Details

    References:

    1. Jiang W, Miyamoto T, Kakizawa T, Sakuma T, Nishio S, Takeda T, Suzuki S, Hashizume K: Expression of thyroid hormone receptor alpha in 3T3-L1 adipocytes; triiodothyronine increases the expression of lipogenic enzyme and triglyceride accumulation. J Endocrinol. 2004 Aug;182(2):295-302. Pubmed
    2. Kariv R, Enden A, Zvibel I, Rosner G, Brill S, Shafritz DA, Halpern Z, Oren R: Triiodothyronine and interleukin-6 (IL-6) induce expression of HGF in an immortalized rat hepatic stellate cell line. Liver Int. 2003 Jun;23(3):187-93. Pubmed
    3. Mai W, Janier MF, Allioli N, Quignodon L, Chuzel T, Flamant F, Samarut J: Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10332-7. Epub 2004 Jul 6. Pubmed
    4. Sciaudone MP, Yao L, Schaller M, Zinn SA, Freake HC: Diethylenetriaminepentaacetic acid enhances thyroid hormone action by a transcriptional mechanism. Biol Trace Elem Res. 2004 Summer;99(1-3):219-31. Pubmed
    5. Timmer DC, Bakker O, Wiersinga WM: Triiodothyronine affects the alternative splicing of thyroid hormone receptor alpha mRNA. J Endocrinol. 2003 Nov;179(2):217-25. Pubmed
    6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

    2. Thyroid hormone receptor beta

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Actions: agonist

    Components

    Name UniProt ID Details
    Thyroid hormone receptor beta P10828 Details

    References:

    1. Bernal J: Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):249-59. Pubmed
    2. Gonzalez-Sancho JM, Garcia V, Bonilla F, Munoz A: Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 2003 Mar 31;192(2):121-32. Pubmed
    3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
    4. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
    5. Yen PM, Feng X, Flamant F, Chen Y, Walker RL, Weiss RE, Chassande O, Samarut J, Refetoff S, Meltzer PS: Effects of ligand and thyroid hormone receptor isoforms on hepatic gene expression profiles of thyroid hormone receptor knockout mice. EMBO Rep. 2003 Jun;4(6):581-7. Pubmed
    6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed
    7. Wu SY, Sadow PM, Refetoff S, Weiss RE: Tissue responses to thyroid hormone in a kindred with resistance to thyroid hormone harboring a commonly occurring mutation in the thyroid hormone receptor beta gene (P453T). J Lab Clin Med. 2005 Aug;146(2):85-94. Pubmed
    8. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. Pubmed
    9. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. Pubmed

    1. Transthyretin

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Components

    Name UniProt ID Details
    Transthyretin P02766 Details

    References:

    1. Eneqvist T, Lundberg E, Karlsson A, Huang S, Santos CR, Power DM, Sauer-Eriksson AE: High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine. J Biol Chem. 2004 Jun 18;279(25):26411-6. Epub 2004 Apr 13. Pubmed
    2. Palha JA: Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 2002 Dec;40(12):1292-300. Pubmed

    2. Thyroxine-binding globulin

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Components

    Name UniProt ID Details
    Thyroxine-binding globulin P05543 Details

    References:

    1. Palha JA: Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 2002 Dec;40(12):1292-300. Pubmed

    3. Serum albumin

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Components

    Name UniProt ID Details
    Serum albumin P02768 Details

    References:

    1. Palha JA: Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 2002 Dec;40(12):1292-300. Pubmed

    1. Solute carrier organic anion transporter family member 1A2

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 1A2 P46721 Details

    References:

    1. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. Pubmed
    2. Friesema EC, Docter R, Moerings EP, Stieger B, Hagenbuch B, Meier PJ, Krenning EP, Hennemann G, Visser TJ: Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501. Pubmed
    3. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. Pubmed

    2. Solute carrier organic anion transporter family member 1B1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 1B1 Q9Y6L6 Details

    References:

    1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63. Pubmed
    2. Kullak-Ublick, G.A. et al. Organic anion-transporting polypeptide B (OATP- B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001). Pubmed

    3. Solute carrier organic anion transporter family member 1B3

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 1B3 Q9NPD5 Details

    References:

    1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. Pubmed
    2. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. Pubmed

    4. Solute carrier organic anion transporter family member 4C1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 4C1 Q6ZQN7 Details

    References:

    1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. Pubmed

    5. Sodium/bile acid cotransporter

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate

    Components

    Name UniProt ID Details
    Sodium/bile acid cotransporter Q14973 Details

    References:

    1. Friesema EC, Docter R, Moerings EP, Stieger B, Hagenbuch B, Meier PJ, Krenning EP, Hennemann G, Visser TJ: Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501. Pubmed

    6. Solute carrier organic anion transporter family member 1C1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate inhibitor

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 1C1 Q9NYB5 Details

    References:

    1. Tohyama K, Kusuhara H, Sugiyama Y: Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91. Epub 2004 May 27. Pubmed
    2. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. Pubmed

    7. Solute carrier organic anion transporter family member 4A1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate inhibitor

    Components

    Name UniProt ID Details
    Solute carrier organic anion transporter family member 4A1 Q96BD0 Details

    References:

    1. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. Pubmed
    2. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. Pubmed
    1. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. Pubmed

    8. Solute carrier family 22 member 8

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Solute carrier family 22 member 8 Q8TCC7 Details

    References:

    1. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. Pubmed

    9. Monocarboxylate transporter 10

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inhibitor

    Components

    Name UniProt ID Details
    Monocarboxylate transporter 10 Q8TF71 Details

    References:

    1. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. Pubmed

    10. Multidrug resistance protein 1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: inducer

    Components

    Name UniProt ID Details
    Multidrug resistance protein 1 P08183 Details

    References:

    1. Ashida K, Katsura T, Motohashi H, Saito H, Inui K: Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G617-23. Pubmed

    11. Large neutral amino acids transporter small subunit 1

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Components

    Name UniProt ID Details
    Large neutral amino acids transporter small subunit 1 Q01650 Details

    References:

    1. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H: Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002 Apr;61(4):729-37. Pubmed

    Comments
    Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:09